x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012233
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IHC |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala73 of human LCN2 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | LCN2 |
| UniProt No. | P80188 |
| Gene ID | 3934 |
| Gene Description | Lipocalin 2, also known as neutrophil gelatinase-associated lipocalin, belongs to the lipocalin family. Proteins in this family exhibit considerable sequence diversity, but share a highly conserved structure composed of an eight-stranded antiparallel beta-barrel that encloses an internal ligand-binding site. LCN2 is considered as an iron transporter. LCN2 can bind bacterial siderophores and inhibits bacterial growth by iron depletion. It can also bind endogenous compounds like catechol in complex with iron. LCN2 was originally identified in neutrophils, and its expression was induced in many other tissues like kidney and liver in response to various pathologic states, such as infection, ischemia, and acute kidney injury. LCN2 is considered a biomarker for conditions like ischemic stroke, acute kidney injury, inflammatory and metabolic diseases. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
